{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:53:13Z","timestamp":1791859993859,"version":"4.3.4"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11260-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:08:12Z","timestamp":1750637292000},"page":"197-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pyrazole in drug development: a medicinal-chemistry based analysis of USFDA-approved drugs in last decade"],"prefix":"10.1007","volume":"30","author":[{"given":"Nisha","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elagandhula","family":"Sathish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arockia","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay M.","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glowi","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"5","key":"11260_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/acs.jmedchem.0c01786","volume":"64","author":"P Bhutani","year":"2021","unstructured":"Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna PK, Bhutani H, Paul AT, Kumar R (2021) U.S. FDA approved drugs from 2015\u2013June 2020: a perspective. J Med Chem 64(5):2339\u20132381. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01786","journal-title":"J Med Chem"},{"issue":"28","key":"11260_CR2","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1039\/c6ob00936k","volume":"14","author":"AP Taylor","year":"2016","unstructured":"Taylor AP, Robinson RP, Fobian YM, Blakemore DC, Jones LH, Fadeyi O (2016) Modern advances in heterocyclic chemistry in drug discovery. Org Biomol Chem 14(28):6611\u20136637. https:\/\/doi.org\/10.1039\/c6ob00936k","journal-title":"Org Biomol Chem"},{"key":"11260_CR3","volume-title":"Progress in heterocyclic chemistry","author":"G Gribble","year":"2009","unstructured":"Gribble G, Joule J (2009) Progress in heterocyclic chemistry. Elsevier, Amsterdam"},{"key":"11260_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24213839","author":"J Jampilek","year":"2019","unstructured":"Jampilek J (2019) Heterocycles in medicinal chemistry. Molecules (Basel, Switzerland). https:\/\/doi.org\/10.3390\/molecules24213839","journal-title":"Molecules (Basel, Switzerland)"},{"key":"11260_CR5","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.rechem.2022.100606","volume":"4","author":"E Kabir","year":"2022","unstructured":"Kabir E, Uzzaman M (2022) A review on biological and medicinal impact of heterocyclic compounds. Results Chem 4:100606. https:\/\/doi.org\/10.1016\/j.rechem.2022.100606","journal-title":"Results Chem"},{"issue":"9","key":"11260_CR6","first-page":"2947","volume":"3","author":"P Arora","year":"2012","unstructured":"Arora P, Arora V, Lamba HS, Wadhwa D (2012) Importance of heterocyclic chemistry: a review. Int J Pharm Sci Res 3(9):2947","journal-title":"Int J Pharm Sci Res"},{"issue":"13","key":"11260_CR7","first-page":"141","volume":"9","author":"A Al-Mulla","year":"2017","unstructured":"Al-Mulla A (2017) A review: biological importance of heterocyclic compounds. Der Pharma Chemica 9(13):141\u2013147","journal-title":"Der Pharma Chemica"},{"issue":"4","key":"11260_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","volume":"49","author":"JH Lin","year":"1997","unstructured":"Lin JH, Lu AYH (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49(4):403\u2013449","journal-title":"Pharmacol Rev"},{"issue":"13","key":"11260_CR9","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/jm300343m","volume":"55","author":"DJ St. Jean Jr","year":"2012","unstructured":"St. Jean DJ Jr, Fotsch C (2012) Mitigating heterocycle metabolism in drug discovery. J Med Chem 55(13):6002\u20136020. https:\/\/doi.org\/10.1021\/jm300343m","journal-title":"J Med Chem"},{"key":"11260_CR10","doi-asserted-by":"publisher","first-page":"116838","DOI":"10.1016\/j.ejmech.2024.116838","volume":"279","author":"W Luo","year":"2024","unstructured":"Luo W, Liu Y, Qin H, Zhao Z, Wang S, He W, Tang S, Peng J (2024) Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: synthesis and biological activity. Eur J Med Chem 279:116838. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116838","journal-title":"Eur J Med Chem"},{"key":"11260_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081909","author":"N Kerru","year":"2020","unstructured":"Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB (2020) A Review on recent advances in nitrogen-containing molecules and their biological applications. Molecules (Basel, Switzerland). https:\/\/doi.org\/10.3390\/molecules25081909","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"14","key":"11260_CR12","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","volume":"67","author":"CM Marshall","year":"2024","unstructured":"Marshall CM, Federice JG, Bell CN, Cox PB, Njardarson JT (2024) An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u20132023). J Med Chem 67(14):11622\u201311655. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01122","journal-title":"J Med Chem"},{"key":"11260_CR13","first-page":"347","volume-title":"Advances in heterocyclic chemistry","author":"AN Kost","year":"1966","unstructured":"Kost AN, Grandberg II (1966) Progress in pyrazole chemistry. Advances in heterocyclic chemistry. Elsevier, Amsterdam, pp 347\u2013429"},{"key":"11260_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.077","volume":"120","author":"MF Khan","year":"2016","unstructured":"Khan MF, Alam MM, Verma G, Akhtar W, Akhter M, Shaquiquzzaman M (2016) The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 120:170\u2013201. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.077","journal-title":"Eur J Med Chem"},{"issue":"2","key":"11260_CR15","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/cber.188301602194","volume":"16","author":"L Knorr","year":"1883","unstructured":"Knorr L (1883) Einwirkung von acetessigester auf phenylhydrazin. Ber Dtsch Chem Ges 16(2):2597\u20132599","journal-title":"Ber Dtsch Chem Ges"},{"issue":"4688","key":"11260_CR16","doi-asserted-by":"publisher","first-page":"BA69","DOI":"10.1038\/184069a0b","volume":"184","author":"FF Noe","year":"1959","unstructured":"Noe FF, Fowden L (1959) \u03b1-Amino-\u03b2-(pyrazolyl-N) propionic acid: a new amino-acid from Citrullus vulgaris (Water Melon). Nature 184(4688):BA69\u2013BA70. https:\/\/doi.org\/10.1038\/184069a0b","journal-title":"Nature"},{"issue":"21","key":"11260_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4155\/fmc-2023-0207","volume":"15","author":"MA Alam","year":"2023","unstructured":"Alam MA (2023) Pyrazole: an emerging privileged scaffold in drug discovery. Fut Med Chem 15(21):2011\u20132023. https:\/\/doi.org\/10.4155\/fmc-2023-0207","journal-title":"Fut Med Chem"},{"issue":"11","key":"11260_CR18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1039\/D2MD00206J","volume":"13","author":"G Li","year":"2022","unstructured":"Li G, Cheng Y, Han C, Song C, Huang N, Du Y (2022) Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies. RSC Med Chem 13(11):1300\u20131321","journal-title":"RSC Med Chem"},{"issue":"1","key":"11260_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10534-011-9496-4","volume":"25","author":"FK Keter","year":"2012","unstructured":"Keter FK, Darkwa J (2012) Perspective: the potential of pyrazole-based compounds in medicine. Biometals 25(1):9\u201321. https:\/\/doi.org\/10.1007\/s10534-011-9496-4","journal-title":"Biometals"},{"issue":"2","key":"11260_CR20","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/cber.18890220284","volume":"22","author":"E Buchner","year":"1889","unstructured":"Buchner E (1889) Ein isomeres des glyxalins. Ber Dtsch Chem Ges 22(2):2165\u20132167","journal-title":"Ber Dtsch Chem Ges"},{"issue":"11","key":"11260_CR21","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1021\/cr2000459","volume":"111","author":"S Fustero","year":"2011","unstructured":"Fustero S, S\u00e1nchez-Rosell\u00f3 M, Barrio P, Simon-Fuentes A (2011) From 2000 to mid-2010: a fruitful decade for the synthesis of pyrazoles. Chem Rev 111(11):6984\u20137034. https:\/\/doi.org\/10.1021\/cr2000459","journal-title":"Chem Rev"},{"issue":"3","key":"11260_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/reactions4030029","volume":"4","author":"I Ameziane El Hassani","year":"2023","unstructured":"Ameziane El Hassani I, Rouzi K, Assila H, Karrouchi K, Ansar MH (2023) Recent advances in the synthesis of pyrazole derivatives: a review. Reactions 4(3):478\u2013504","journal-title":"Reactions"},{"issue":"23","key":"11260_CR23","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1021\/acs.orglett.0c03465","volume":"22","author":"H Matsuzaki","year":"2020","unstructured":"Matsuzaki H, Takeda N, Yasui M, Ito Y, Konishi K, Ueda M (2020) Synthesis of pyrazoles utilizing the ambiphilic reactivity of hydrazones. Org Lett 22(23):9249\u20139252. https:\/\/doi.org\/10.1021\/acs.orglett.0c03465","journal-title":"Org Lett"},{"issue":"1","key":"11260_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.cclet.2021.05.008","volume":"33","author":"G Yang","year":"2022","unstructured":"Yang G, Liu Y, Lin X, Ming B, Li K, Hu C (2022) Self-assembly of a new 3D platelike ternary-oxo-cluster: an efficient catalyst for the synthesis of pyrazoles. Chinese Chem Lett 33(1):354\u2013357","journal-title":"Chinese Chem Lett"},{"issue":"13","key":"11260_CR25","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1021\/ol060570p","volume":"8","author":"ST Heller","year":"2006","unstructured":"Heller ST, Natarajan SR (2006) 1, 3-diketones from acid chlorides and ketones: a rapid and general one-pot synthesis of pyrazoles. Org Lett 8(13):2675\u20132678. https:\/\/doi.org\/10.1021\/ol060570p","journal-title":"Org Lett"},{"issue":"13","key":"11260_CR26","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1039\/D0QO00476F","volume":"7","author":"AS Komendantova","year":"2020","unstructured":"Komendantova AS, Lyssenko KA, Zavarzin IV, Volkova YA (2020) Iodine-promoted synthesis of pyrazoles from 1, 3-dicarbonyl compounds and oxamic acid thiohydrazides. Org Chem Front 7(13):1640\u20131646","journal-title":"Org Chem Front"},{"issue":"16","key":"11260_CR27","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1021\/acs.orglett.9b02206","volume":"21","author":"J Poletto","year":"2019","unstructured":"Poletto J, Ribeiro GM, da Silva MJ, Jacomini AP, Basso EA, Back DF, Moura S, Rosa FA (2019) One-pot highly regioselective synthesis of \u03b1-ketoamide N-arylpyrazoles from secondary \u03b2-enamino diketones. Org Lett 21(16):6325\u20136328. https:\/\/doi.org\/10.1021\/acs.orglett.9b02206","journal-title":"Org Lett"},{"issue":"22","key":"11260_CR28","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1039\/C9CY01335K","volume":"9","author":"NS Thirukovela","year":"2019","unstructured":"Thirukovela NS, Balaboina R, Botla V, Vadde R, Jonnalagadda SB, Vasam CS (2019) One-pot regioselective synthesis of substituted pyrazoles and isoxazoles in PEG-400\/water medium by Cu-free nano-Pd catalyzed sequential acyl Sonogashira coupling\u2013intramolecular cyclization. Catal Sci Technol 9(22):6471\u20136481","journal-title":"Catal Sci Technol"},{"issue":"52","key":"11260_CR29","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1039\/d2cc01793h","volume":"58","author":"S Katiyar","year":"2022","unstructured":"Katiyar S, Kumar A, Sashidhara KV (2022) Silver-catalyzed decarboxylative cyclization for the synthesis of substituted pyrazoles from 1, 2-diaza-1, 3-dienes and \u03b1-keto acids. Chem Commun 58(52):7297\u20137300. https:\/\/doi.org\/10.1039\/d2cc01793h","journal-title":"Chem Commun"},{"issue":"22","key":"11260_CR30","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1002\/adsc.202200696","volume":"364","author":"SA Paveliev","year":"2022","unstructured":"Paveliev SA, Segida OO, Bityukov OV, Tang HT, Pan YM, Nikishin GI, Terent\u2019ev AO (2022) Electrocatalytic synthesis of substituted pyrazoles via hypervalent iodine mediated intramolecular C\u2212N coupling. Adv Synth Catal 364(22):3910\u20133916","journal-title":"Adv Synth Catal"},{"key":"11260_CR31","first-page":"363","volume":"8","author":"M Salem","year":"2016","unstructured":"Salem M (2016) A convenient route to 5-aminopyrazole, bispyrazole and pyrazolo [1, 5-a] pyrimidines incorporating antipyrine or furan moiety as potent antimicrobial agents. Pharma Chem 8:363\u2013376","journal-title":"Pharma Chem"},{"issue":"2","key":"11260_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acs.chemrev.5b00360","volume":"116","author":"L Zhang","year":"2016","unstructured":"Zhang L, Dong J, Xu X, Liu Q (2016) Chemistry of ketene N, S-acetals: an overview. Chem Rev 116(2):287\u2013322. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00360","journal-title":"Chem Rev"},{"issue":"6","key":"11260_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1021\/acs.orglett.3c04274","volume":"26","author":"Z Zhong","year":"2024","unstructured":"Zhong Z, Ma T-K, White AJ, Bull JA (2024) Synthesis of pyrazolesulfoximines using \u03b1-diazosulfoximines with alkynes. Org Lett 26(6):1178\u20131183. https:\/\/doi.org\/10.1021\/acs.orglett.3c04274","journal-title":"Org Lett"},{"issue":"5","key":"11260_CR34","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1021\/acs.orglett.0c00395","volume":"22","author":"H Wang","year":"2020","unstructured":"Wang H, Ning Y, Sun Y, Sivaguru P, Bi X (2020) Cycloaddition of trifluoroacetaldehyde N-triftosylhydrazone (TFHZ-Tfs) with alkynes for synthesizing 3-trifluoromethylpyrazoles. Org Lett 22(5):2012\u20132016. https:\/\/doi.org\/10.1021\/acs.orglett.0c00395","journal-title":"Org Lett"},{"key":"11260_CR35","doi-asserted-by":"publisher","first-page":"114739","DOI":"10.1016\/j.ejmech.2022.114739","volume":"243","author":"M-M Li","year":"2022","unstructured":"Li M-M, Huang H, Pu Y, Tian W, Deng Y, Lu J (2022) A close look into the biological and synthetic aspects of fused pyrazole derivatives. Eur J Med Chem 243:114739","journal-title":"Eur J Med Chem"},{"key":"11260_CR36","unstructured":"Wiley R, Behr L The chemistry of heterocyclic chemistry: pyrazoles, pyrazolines, pyrazolidines, indazoles and condensed rings, Behr, LC."},{"issue":"40","key":"11260_CR37","doi-asserted-by":"publisher","first-page":"12295","DOI":"10.1016\/S0040-4020(98)00749-2","volume":"54","author":"TM Krygowski","year":"1998","unstructured":"Krygowski TM, Anulewicz R, Cyra\u0144ski MK, Puchala A, Rasala D (1998) Separation of the energetic and geometric contribution to the aromaticity. Part IX. Aromaticity of pyrazoles in dependence on the kind of substitution. Tetrahedron 54(40):12295\u201312300","journal-title":"Tetrahedron"},{"key":"11260_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12039-019-1646-1","volume":"131","author":"M Faisal","year":"2019","unstructured":"Faisal M, Saeed A, Hussain S, Dar P, Larik FA (2019) Recent developments in synthetic chemistry and biological activities of pyrazole derivatives. J Chem Sci 131:1\u201330","journal-title":"J Chem Sci"},{"issue":"4","key":"11260_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acsmedchemlett.9b00611","volume":"11","author":"Z Xin","year":"2020","unstructured":"Xin Z, Himmelbauer MK, Jones JH, Enyedy I, Gilfillan R, Hesson T, King K, Marcotte DJ, Murugan P, Santoro JC (2020) Discovery of CNS-penetrant apoptosis signal-regulating kinase 1 (ASK1) inhibitors. ACS Med Chem Lett 11(4):485\u2013490. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00611","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"11260_CR40","doi-asserted-by":"publisher","first-page":"e100880","DOI":"10.1371\/journal.pone.0100880","volume":"9","author":"M Dumble","year":"2014","unstructured":"Dumble M, Crouthamel M-C, Zhang S-Y, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA (2014) Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE 9(6):e100880. https:\/\/doi.org\/10.1371\/journal.pone.0100880","journal-title":"PLoS ONE"},{"issue":"14","key":"11260_CR41","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.3390\/molecules28145359","volume":"28","author":"GM Nitulescu","year":"2023","unstructured":"Nitulescu GM, Stancov G, Seremet OC, Nitulescu G, Mihai DP, Duta-Bratu CG, Barbuceanu SF, Olaru OT (2023) The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies. Molecules (Basel Switzerland) 28(14):5359","journal-title":"Molecules (Basel Switzerland)"},{"key":"11260_CR42","volume-title":"Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes","author":"T Biftu","year":"2014","unstructured":"Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D (2014) Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. ACS Publications"},{"issue":"17","key":"11260_CR43","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1016\/j.bmc.2013.06.062","volume":"21","author":"N Papastavrou","year":"2013","unstructured":"Papastavrou N, Chatzopoulou M, Pegklidou K, Nicolaou I (2013) 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors. Bioorg Med Chem 21(17):4951\u20134957","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"11260_CR44","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1016\/j.bmcl.2015.05.036","volume":"25","author":"Q Deng","year":"2015","unstructured":"Deng Q, Lim Y-H, Anand R, Yu Y, Kim J-H, Zhou W, Zheng J, Tempest P, Levorse D, Zhang X (2015) Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists. Bioorg Med Chem Lett 25(15):2958\u20132962. https:\/\/doi.org\/10.1016\/j.bmcl.2015.05.036","journal-title":"Bioorg Med Chem Lett"},{"key":"11260_CR45","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901\u2013D906. https:\/\/doi.org\/10.1093\/nar\/gkm958","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"11260_CR46","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin NE, Strawbridge SA (2024) DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res 52(D1):D1265\u2013D1275. https:\/\/doi.org\/10.1093\/nar\/gkad976","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"11260_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","volume":"6","author":"AF Costa","year":"2020","unstructured":"Costa AF, Campos D, Reis CA, Gomes C (2020) Targeting glycosylation: a new road for cancer drug discovery. Trends in cancer 6(9):757\u2013766. https:\/\/doi.org\/10.1016\/j.trecan.2020.04.002","journal-title":"Trends in cancer"},{"issue":"42","key":"11260_CR48","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.2174\/0929867324666170331123648","volume":"24","author":"B Kumar","year":"2017","unstructured":"Kumar B, Singh S, Skvortsova I, Kumar V (2017) Promising targets in anti-cancer drug development: recent updates. Curr Med Chem 24(42):4729\u20134752. https:\/\/doi.org\/10.2174\/0929867324666170331123648","journal-title":"Curr Med Chem"},{"issue":"19","key":"11260_CR49","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441\u20131454","journal-title":"J Natl Cancer Inst"},{"key":"11260_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/B978-0-323-96121-9.00008-5","volume-title":"Current molecular targets of heterocyclic compounds for cancer therapy","author":"D Choudhary","year":"2024","unstructured":"Choudhary D, Kumar B, Thakur A (2024) Cancer and insulin-like growth factor inhibitors Recent advancements and SAR analysis. Current molecular targets of heterocyclic compounds for cancer therapy. Elsevier, pp 161\u2013181"},{"issue":"12","key":"11260_CR51","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tips.2016.09.005","volume":"37","author":"BV Ayyar","year":"2016","unstructured":"Ayyar BV, Arora S, O\u2019Kennedy R (2016) Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol Sci 37(12):1009\u20131028. https:\/\/doi.org\/10.1016\/j.tips.2016.09.005","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"11260_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/1568009616666160928110818","volume":"17","author":"B Kumar","year":"2017","unstructured":"Kumar B, Kumar R, Skvortsova I, Kumar V (2017) Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials. Curr Cancer Drug Targets 17(4):357\u2013375","journal-title":"Curr Cancer Drug Targets"},{"issue":"Suppl 4","key":"11260_CR53","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.3978\/j.issn.2072-1439.2013.07.10","volume":"5","author":"K Zarogoulidis","year":"2013","unstructured":"Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H (2013) Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 5(Suppl 4):S389. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.07.10","journal-title":"J Thorac Dis"},{"issue":"1","key":"11260_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY (2019) Lorlatinib: first global approval. Drugs 79(1):93\u201398. https:\/\/doi.org\/10.1007\/s40265-018-1041-0","journal-title":"Drugs"},{"issue":"8","key":"11260_CR55","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","volume":"17","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17(8):2081\u20132086. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1591","journal-title":"Clin Cancer Res"},{"key":"11260_CR56","doi-asserted-by":"publisher","first-page":"8769","DOI":"10.2147\/OTT.S197244","volume":"12","author":"DA Bastos","year":"2019","unstructured":"Bastos DA, Antonarakis ES (2019) Darolutamide for castration-resistant prostate cancer. OncoTargets Ther 12:8769\u20138777. https:\/\/doi.org\/10.2147\/OTT.S197244","journal-title":"OncoTargets Ther"},{"key":"11260_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cbi.2015.08.009","volume":"240","author":"G Joshi","year":"2015","unstructured":"Joshi G, Singh PK, Negi A, Rana A, Singh S, Kumar R (2015) Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents. Chem-Biol Inter 240:120\u2013133. https:\/\/doi.org\/10.1016\/j.cbi.2015.08.009","journal-title":"Chem-Biol Inter"},{"issue":"3","key":"11260_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1524-4725.1996.tb00312.x","volume":"22","author":"HM Gloster Jr","year":"1996","unstructured":"Gloster HM Jr, Brodland DG (1996) The epidemiology of skin cancer. Dermatol Surg 22(3):217\u2013226. https:\/\/doi.org\/10.1111\/j.1524-4725.1996.tb00312.x","journal-title":"Dermatol Surg"},{"issue":"12","key":"11260_CR59","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M (2018) Encorafenib and binimetinib: first global approvals. Drugs 78(12):1277\u20131284. https:\/\/doi.org\/10.1007\/s40265-018-0963-x","journal-title":"Drugs"},{"issue":"9976","key":"11260_CR60","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385(9976):1447\u20131459. https:\/\/doi.org\/10.1016\/S0140-6736(13)62120-0","journal-title":"Lancet"},{"issue":"2","key":"11260_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED (2022) Asciminib: first approval. Drugs 82(2):219\u2013226. https:\/\/doi.org\/10.1007\/s40265-021-01662-3","journal-title":"Drugs"},{"issue":"4","key":"11260_CR62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<661::AID-CNCR7>3.0.CO;2-O","volume":"82","author":"Y Takebayashi","year":"1998","unstructured":"Takebayashi Y, Akiyama SI, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T, Aikou T (1998) The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer: Interdis Int J Am Cancer Soc 82(4):661\u2013666","journal-title":"Cancer: Interdis Int J Am Cancer Soc"},{"issue":"4","key":"11260_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Avapritinib: first approval. Drugs 80(4):433\u2013439. https:\/\/doi.org\/10.1007\/s40265-020-01275-2","journal-title":"Drugs"},{"issue":"26","key":"11260_CR64","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL (2022) Mantle-cell lymphoma. New Eng J Med 386(26):2495\u20132506","journal-title":"New Eng J Med"},{"issue":"6","key":"11260_CR65","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Pirtobrutinib: first approval. Drugs 83(6):547\u2013553. https:\/\/doi.org\/10.1007\/s40265-023-01860-1","journal-title":"Drugs"},{"issue":"1","key":"11260_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Zanubrutinib: first approval. Drugs 80(1):91\u201397. https:\/\/doi.org\/10.1007\/s40265-019-01252-4","journal-title":"Drugs"},{"issue":"6","key":"11260_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA (2019) Bruton tyrosine kinase inhibitors: present and future. Cancer J 25(6):386\u2013393. https:\/\/doi.org\/10.1097\/PPO.0000000000000412","journal-title":"Cancer J"},{"issue":"17","key":"11260_CR68","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Pralsetinib: first approval. Drugs 80(17):1865\u20131870. https:\/\/doi.org\/10.1007\/s40265-020-01427-4","journal-title":"Drugs"},{"key":"11260_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","volume":"128","author":"R Roskoski Jr","year":"2018","unstructured":"Roskoski R Jr, Sadeghi-Nejad A (2018) Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res 128:1\u201317. https:\/\/doi.org\/10.1016\/j.phrs.2017.12.021","journal-title":"Pharmacol Res"},{"issue":"9","key":"11260_CR70","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Erdafitinib: first global approval. Drugs 79(9):1017\u20131021. https:\/\/doi.org\/10.1007\/s40265-019-01142-9","journal-title":"Drugs"},{"key":"11260_CR71","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","volume":"151","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res 151:104567","journal-title":"Pharmacol Res"},{"key":"11260_CR72","doi-asserted-by":"crossref","unstructured":"Cicenas J, Zalyte E, Bairoch A, Gaudet P (2018) Kinases and cancer, MDPI, p. 63","DOI":"10.3390\/cancers10030063"},{"key":"11260_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/B978-0-323-96121-9.00006-1","volume-title":"Current molecular targets of heterocyclic compounds for cancer therapy","author":"NK Nandi","year":"2024","unstructured":"Nandi NK, Bhatia R, Chauhan G, Kalra S, Kumar B (2024) Cyclin-dependent kinase 4 and 6 in cancer: exploration of CDK4\/6 inhibitors as anticancer agents. Current molecular targets of heterocyclic compounds for cancer therapy. Elsevier, Amsterdam, pp 115\u2013137"},{"issue":"12","key":"11260_CR74","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","volume":"18","author":"R Kannaiyan","year":"2018","unstructured":"Kannaiyan R, Mahadevan D (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Therapy 18(12):1249\u20131270. https:\/\/doi.org\/10.1080\/14737140.2018.1527688","journal-title":"Expert Rev Anticancer Therapy"},{"key":"11260_CR75","first-page":"43","volume-title":"Seminars in cell & developmental biology","author":"WJ Israelsen","year":"2015","unstructured":"Israelsen WJ, VanderHeiden MG (2015) Pyruvate kinase: function, regulation and role in cancer. Seminars in cell & developmental biology. Elsevier, Amsterdam, pp 43\u201351"},{"key":"11260_CR76","doi-asserted-by":"crossref","unstructured":"Dwivedi AR, Jaiswal S, Kukkar D, Kumar R, Singh TG, Singh MP, Gaidhane AM, Lakhanpal S, Prasad KN, Kumar B (2024) A decade of pyridine containing heterocycles in the approved USFDA drugs: a medicinal chemistry-based analysis, RSC Med Chem","DOI":"10.1039\/D4MD00632A"},{"issue":"1","key":"11260_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 17(1):1\u201320. https:\/\/doi.org\/10.1186\/s12943-018-0804-2","journal-title":"Mol Cancer"},{"issue":"7","key":"11260_CR78","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discovery 20(7):551\u2013569. https:\/\/doi.org\/10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"11260_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel P-R, Tullis E, Casta\u00f1os C, Castellani C (2020) The future of cystic fibrosis care: a global perspective. Lancet Resp Med 8(1):65\u2013124. https:\/\/doi.org\/10.1016\/S2213-2600(19)30337-6","journal-title":"Lancet Resp Med"},{"issue":"18","key":"11260_CR80","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Elexacaftor\/ivacaftor\/tezacaftor: first approval. Drugs 79(18):2001\u20132007. https:\/\/doi.org\/10.1007\/s40265-019-01233-7","journal-title":"Drugs"},{"issue":"1","key":"11260_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2004.05.007","volume":"114","author":"AE Davis Iii","year":"2005","unstructured":"Davis Iii AE (2005) The pathophysiology of hereditary angioedema. Clin Immunol 114(1):3\u20139","journal-title":"Clin Immunol"},{"issue":"3","key":"11260_CR82","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-021-01475-4","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A (2021) Berotralstat: first approval. Drugs 81(3):405\u2013409. https:\/\/doi.org\/10.1007\/s40265-021-01475-4","journal-title":"Drugs"},{"key":"11260_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-6-80","volume":"6","author":"RJ Pignolo","year":"2011","unstructured":"Pignolo RJ, Shore EM, Kaplan FS (2011) Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 6:1\u20136. https:\/\/doi.org\/10.1186\/1750-1172-6-80","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"11260_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s44162-024-00032-3","volume":"3","author":"M Talha","year":"2024","unstructured":"Talha M, Ali MH (2024) Palovarotene approved as first treatment for fibrodysplasia ossificans progressiva (FOP). J Rare Dis 3(1):8","journal-title":"J Rare Dis"},{"issue":"10091","key":"11260_CR85","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR (2017) Sickle cell disease. Lancet 390(10091):311\u2013323","journal-title":"Lancet"},{"issue":"2","key":"11260_CR86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA (2020) Voxelotor: first approval. Drugs 80(2):209\u2013215. https:\/\/doi.org\/10.1007\/s40265-020-01262-7","journal-title":"Drugs"},{"issue":"14","key":"11260_CR87","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Lenacapavir: first approval. Drugs 82(14):1499\u20131504. https:\/\/doi.org\/10.1007\/s40265-022-01786-0","journal-title":"Drugs"},{"issue":"7","key":"11260_CR88","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-017-0737-x","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Telotristat ethyl: first global approval. Drugs 77(7):793\u2013798. https:\/\/doi.org\/10.1007\/s40265-017-0737-x","journal-title":"Drugs"},{"issue":"6","key":"11260_CR89","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.neuropharm.2008.07.016","volume":"55","author":"R Spiller","year":"2008","unstructured":"Spiller R (2008) Serotonin and GI clinical disorders. Neuropharmacol 55(6):1072\u20131080. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.07.016","journal-title":"Neuropharmacol"},{"issue":"2","key":"11260_CR90","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ (2016) Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs 76(2):231\u2013242. https:\/\/doi.org\/10.1007\/s40265-015-0524-5","journal-title":"Drugs"},{"issue":"1","key":"11260_CR91","first-page":"1","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, Van Den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3(1):1\u201319","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"11260_CR92","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","volume":"171","author":"JD Rothstein","year":"2017","unstructured":"Rothstein JD (2017) Edaravone: a new drug approved for ALS. Cell 171(4):725. https:\/\/doi.org\/10.1016\/j.cell.2017.10.011","journal-title":"Cell"},{"key":"11260_CR93","doi-asserted-by":"publisher","first-page":"134671","DOI":"10.1016\/j.molstruc.2022.134671","volume":"1276","author":"NK Nandi","year":"2023","unstructured":"Nandi NK, Bhatia R, Saini S, Rawat R, Sharma S, Raj K, Rangra N, Kumar B (2023) Design, synthesis, pharmacological and in silico screening of disubstituted-piperazine derivatives as selective and reversible MAO-A inhibitors for treatment of depression. J Mol Struct 1276:134671","journal-title":"J Mol Struct"},{"key":"11260_CR94","doi-asserted-by":"publisher","first-page":"107148","DOI":"10.1016\/j.bioorg.2024.107148","volume":"144","author":"NK Nandi","year":"2024","unstructured":"Nandi NK, Das S, Choudhary D, Saini S, Bhatia R, Chawla P, Kaur R, Kalra S, Rawat R, Eyupoglu V (2024) Exploration of oxadiazole clubbed benzhydrylpiperazine pharmacophoric features as structural feature for antidepressant activity: In vitro, in vivo and in silico analysis. Bioorg Chem 144:107148","journal-title":"Bioorg Chem"},{"issue":"5","key":"11260_CR95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/0115680266280249240126052505","volume":"24","author":"D Choudhary","year":"2024","unstructured":"Choudhary D, Kaur R, Singh TG, Kumar B (2024) Pyrazoline derivatives as promising MAO\u2013A targeting antidepressants: an update. Curr Top Med Chem 24(5):401\u2013415","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"11260_CR96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/wps.20580","volume":"18","author":"J Ormel","year":"2019","unstructured":"Ormel J, Cuijpers P, Jorm AF, Schoevers R (2019) Prevention of depression will only succeed when it is structurally embedded and targets big determinants. World Psychiatry 18(1):111","journal-title":"World Psychiatry"},{"issue":"10","key":"11260_CR97","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1038\/tp.2016.181","volume":"6","author":"K Ma","year":"2016","unstructured":"Ma K, Xu A, Cui S, Sun M, Xue Y, Wang J (2016) Impaired GABA synthesis, uptake and release are associated with depression-like behaviors induced by chronic mild stress. Transl Psychiatry 6(10):e910\u2013e910. https:\/\/doi.org\/10.1038\/tp.2016.181","journal-title":"Transl Psychiatry"},{"issue":"36","key":"11260_CR98","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.2174\/0929867328666211115124149","volume":"29","author":"A Della Vecchia","year":"2022","unstructured":"Della Vecchia A, Arone A, Piccinni A, Mucci F, Marazziti D (2022) GABA system in depression: impact on pathophysiology and psychopharmacology. Curr Med Chem 29(36):5710\u20135730. https:\/\/doi.org\/10.2174\/0929867328666211115124149","journal-title":"Curr Med Chem"},{"issue":"1","key":"11260_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","volume":"62","author":"H M\u00f6hler","year":"2012","unstructured":"M\u00f6hler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62(1):42\u201353","journal-title":"Neuropharmacology"},{"key":"11260_CR100","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","volume":"57","author":"JR Atack","year":"2009","unstructured":"Atack JR (2009) Subtype-selective GABAA receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv Pharmacol 57:137\u2013185. https:\/\/doi.org\/10.1016\/S1054-3589(08)57004-9","journal-title":"Adv Pharmacol"},{"issue":"6","key":"11260_CR101","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Baricitinib: first global approval. Drugs 77(6):697\u2013704. https:\/\/doi.org\/10.1007\/s40265-017-0723-3","journal-title":"Drugs"},{"issue":"9","key":"11260_CR102","first-page":"1650","volume":"32","author":"JG Walker","year":"2005","unstructured":"Walker JG, Smith MD (2005) The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32(9):1650\u20131653","journal-title":"J Rheumatol"},{"issue":"10","key":"11260_CR103","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/bjo.71.10.766","volume":"71","author":"R David","year":"1987","unstructured":"David R, Zangwill L, Stone D, Yassur Y (1987) Epidemiology of intraocular pressure in a population screened for glaucoma. Br J Ophthalmol 71(10):766\u2013771. https:\/\/doi.org\/10.1136\/bjo.71.10.766","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"11260_CR104","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/jop.2023.0058","volume":"39","author":"H-T Kuo","year":"2023","unstructured":"Kuo H-T, Yeh C-Y, Hsu AY, Ho JH-C, Lin C-J, Tsai Y-Y (2023) Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: a meta-analysis. J Ocul Pharmacol Ther 39(10):705\u2013715. https:\/\/doi.org\/10.1089\/jop.2023.0058","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"11260_CR105","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/138945010790711996","volume":"11","author":"MZ Hernandes","year":"2010","unstructured":"Hernandes MZ, Cavalcanti SMT, Moreira DRM, de Azevedo WF, Leite ACL (2010) Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets 11(3):303\u2013314. https:\/\/doi.org\/10.2174\/138945010790711996","journal-title":"Curr Drug Targets"},{"issue":"8","key":"11260_CR106","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/17460441.2019.1619692","volume":"14","author":"PJ Costa","year":"2019","unstructured":"Costa PJ, Nunes R, Vila-Vi\u00e7osa D (2019) Halogen bonding in halocarbon-protein complexes and computational tools for rational drug design. Expert Opin Drug Discov 14(8):805\u2013820. https:\/\/doi.org\/10.1080\/17460441.2019.1619692","journal-title":"Expert Opin Drug Discov"},{"issue":"11","key":"11260_CR107","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1021\/ci400257k","volume":"53","author":"S Sirimulla","year":"2013","unstructured":"Sirimulla S, Bailey JB, Vegesna R, Narayan M (2013) Halogen interactions in protein\u2013ligand complexes: implications of halogen bonding for rational drug design. J Chem Inf Model 53(11):2781\u20132791","journal-title":"J Chem Inf Model"},{"issue":"5","key":"11260_CR108","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1517\/17460441.2012.678829","volume":"7","author":"Y Lu","year":"2012","unstructured":"Lu Y, Liu Y, Xu Z, Li H, Liu H, Zhu W (2012) Halogen bonding for rational drug design and new drug discovery. Expert Opin Drug Discov 7(5):375\u2013383. https:\/\/doi.org\/10.1517\/17460441.2012.678829","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"11260_CR109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1021\/cc0000388","volume":"3","author":"TI Oprea","year":"2001","unstructured":"Oprea TI, Gottfries J (2001) Chemography: the art of navigating in chemical space. J Comb Chem 3(2):157\u2013166. https:\/\/doi.org\/10.1021\/cc0000388","journal-title":"J Comb Chem"},{"issue":"1","key":"11260_CR110","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci400539q","volume":"54","author":"Z Xu","year":"2014","unstructured":"Xu Z, Yang Z, Liu Y, Lu Y, Chen K, Zhu W (2014) Halogen bond: its role beyond drug\u2013target binding affinity for drug discovery and development. J Chem Inf Model 54(1):69\u201378","journal-title":"J Chem Inf Model"},{"key":"11260_CR111","unstructured":"Maestro S (2020), Maestro, Schr\u00f6dinger, LLC, New York, NY 2020 682"},{"issue":"6","key":"11260_CR112","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","volume":"3","author":"A Shiba-Ishii","year":"2022","unstructured":"Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN (2022) Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer 3(6):710\u2013722. https:\/\/doi.org\/10.1038\/s43018-022-00399-6","journal-title":"Nature Cancer"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11260-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11260-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11260-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:56:43Z","timestamp":1771775803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11260-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11260"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11260-0","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}